Effect of Citalopram on Health status, anxiety and depression in patients with chronic Obstructive pulmonary disease: a pilot study
| ISRCTN | ISRCTN41544517 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN41544517 |
| Protocol serial number | N/A |
| Sponsor | North East Wales NHS Trust (UK) |
| Funder | North East Wales NHS Trust (UK) - Research and Development Fund |
- Submission date
- 07/08/2007
- Registration date
- 21/04/2008
- Last edited
- 11/10/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Christian P Subbe
Scientific
Scientific
77 Brook Lane
Chester
LL13 7TD
United Kingdom
| Phone | +44 (0)1978 291100 |
|---|---|
| csubbe@hotmail.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Single-centre randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Effect of Citalopram on Health status, anxiety and depression in patients with chronic Obstructive pulmonary disease: a pilot study |
| Study acronym | ECHO |
| Study objectives | Chronic obstructive pulmonary disease (COPD) sufferers often experience a vicious circle of breathlessness and anxiety. These symptoms commonly lead to reduced physical activity, progressive loss of fitness, increasing social isolation and depression (which often goes undiagnosed). If this circle could be broken improved physical functioning and quality of life might result. |
| Ethics approval(s) | North Wales Health Authority Research Ethics Committee, 05/02/2003 |
| Health condition(s) or problem(s) studied | Chronic obstructive pulmonary disease (COPD) |
| Intervention | Matching oral citalopram 20 mg and placebo, starting with half a tablet once per day for two weeks, then one tablet per day for the remaining weeks with monthly follow up for three months and a two week period of half a tablet per day prior to discontinuation of treatment. |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Citalopram |
| Primary outcome measure(s) |
Health-related quality of life, measured using St Georges Respiratory Questionnaire at baseline and 3 months |
| Key secondary outcome measure(s) |
1. Depression and anxiety, measured using the Hospital Anxiety and Depression Score (HADS) at baseline and 3 months |
| Completion date | 01/08/2004 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 20 |
| Key inclusion criteria | 1. Diagnosis of COPD 2. Clinical diagnosis of anxiety or depression 3. Adults of either sex |
| Key exclusion criteria | 1. Severe ischaemic heart disease 2. On treatment for anxiety or depression 3. Terminal illness |
| Date of first enrolment | 01/08/2003 |
| Date of final enrolment | 01/08/2004 |
Locations
Countries of recruitment
- United Kingdom
- Wales
Study participating centre
77 Brook Lane
Chester
LL13 7TD
United Kingdom
LL13 7TD
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
11/10/2017: No publications found, verifying study status with principal investigator.
